Nektar Therapeutics buy tinelchen
Start price
19.04.22
/
0%
€4.42
Target price
19.04.23
-
Performance (%)
-2.94%
End price
02.05.22
€4.29
Summary
This prediction ended on 02.05.22 with a price of €4.29. With a performance of -2.94%, the BUY prediction for Nektar Therapeutics by tinelchen closed slightly in the red. This prediction was marked as speculative and is excluded from tinelchen's performance statistics.Nektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Nektar Therapeutics | - | - | - | - |
| iShares Core DAX® | 0.734% | 1.458% | 17.980% | 65.292% |
| iShares Nasdaq 100 | -2.686% | -0.146% | 3.810% | 97.467% |
| iShares Nikkei 225® | -2.261% | -2.729% | 11.679% | 39.755% |
| iShares S&P 500 | -1.346% | 0.467% | 1.970% | 61.093% |
According to tinelchen what are the pros and cons of Nektar Therapeutics for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by tinelchen for this prediction
In the thread Nektar Therapeutics diskutieren
Buy Nektar Therapeutics